Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02870231 · ClinicalTrials.gov registry record · Phase 1
Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 187
- Enrollment target
NCT02870231: Completed Phase 1 study, sponsored by Novo Nordisk A/S.
NCT02870231 is a Phase 1 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 187 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (212% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02870231, a Phase 1 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 187 participants
- Enrollment target
Study Summary
This trial is conducted in the United States of America. The aim of this trial is to investigate Safety, Tolerability, PK (the exposure of the trial drug in the body) and PD (the effect of the investigated drug on the body) for Multiple Doses of NNC9204-0530 in Combination with Liraglutide in Male and Female Subjects being Overweight or with Obesity
Interventions
- DRUG placebo
- DRUG liraglutide
- DRUG NNC9204-0530
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 187 participants |
| Start Date | 2016-08-18 |
| Est. Completion | 2017-09-03 |
| Phase | Phase 1 |
What the finished NCT02870231 record still lists
NCT02870231 is an interventional study that assigns participants to a tested intervention. The registered 187 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (212% higher).
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT02870231 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02870231 about?
NCT02870231 is a clinical study titled "Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity". This trial is conducted in the United States of America. The aim of this trial is to investigate Safety, Tolerability, PK (the exposure of the trial drug in the body) and PD (the effect of the investigated drug on the body) for Multiple Doses of NNC9204-0530 in Combination with Liraglutide in Male a...
What is the current status of trial NCT02870231?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 187 participants. The study started on 2016-08-18. Estimated completion is 2017-09-03.
What interventions are being tested in trial NCT02870231?
The interventions under investigation include: placebo (DRUG), liraglutide (DRUG), NNC9204-0530 (DRUG).
Who is sponsoring clinical trial NCT02870231?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02870231's enrollment target sits among peer trials
187 290th of 2000 higher than 1,710 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06153251 · 187 participants · Phase 1
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
- NCT06254898 · 187 participants · NA
Use of Incentives for Stressful Medical Procedures
- NCT07062237 · 187 participants · NA
A Randomized Clinical Trial Comparing Embryo Euploidy Rates Following Ultrashort Versus Standard Abstinence
- NCT07217574 · 187 participants
Program in Oncology for Tribal Health Systems.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI